Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

405 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tumor-intrinsic sensitivity to the pro-apoptotic effects of IFN-γ is a major determinant of CD4+ CAR T-cell antitumor activity.
Boulch M, Cazaux M, Cuffel A, Guerin MV, Garcia Z, Alonso R, Lemaître F, Beer A, Corre B, Menger L, Grandjean CL, Morin F, Thieblemont C, Caillat-Zucman S, Bousso P. Boulch M, et al. Among authors: thieblemont c. Nat Cancer. 2023 Jul;4(7):968-983. doi: 10.1038/s43018-023-00570-7. Epub 2023 May 29. Nat Cancer. 2023. PMID: 37248395 Free PMC article.
Kidney Transplant T Cell-Mediated Rejection Occurring After Anti-CD19 CAR T-Cell Therapy for Refractory Aggressive Burkitt-like Lymphoma With 11q Aberration: A Case Report.
de Nattes T, Camus V, François A, Dallet G, Ferrand C, Guerrot D, Lemoine M, Morin F, Thieblemont C, Veresezan EL, Candon S, Latouche JB, Bertrand D. de Nattes T, et al. Among authors: thieblemont c. Am J Kidney Dis. 2022 May;79(5):760-764. doi: 10.1053/j.ajkd.2021.07.012. Epub 2021 Aug 27. Am J Kidney Dis. 2022. PMID: 34461166
Effect of early granulocyte-colony-stimulating factor administration in the prevention of febrile neutropenia and impact on toxicity and efficacy of anti-CD19 CAR-T in patients with relapsed/refractory B-cell lymphoma.
Liévin R, Di Blasi R, Morin F, Galli E, Allain V, De Jorna R, Vercellino L, Parquet N, Mebarki M, Larghero J, de Kerviler E, Madelaine I, Caillat-Zucman S, Chevret S, Thieblemont C. Liévin R, et al. Among authors: thieblemont c. Bone Marrow Transplant. 2022 Mar;57(3):431-439. doi: 10.1038/s41409-021-01526-0. Epub 2022 Jan 30. Bone Marrow Transplant. 2022. PMID: 35094012 Free PMC article.
Real-world characteristics of T-cell apheresis and clinical response to tisagenlecleucel in B-cell lymphoma.
Cuffel A, Allain V, Faivre L, Di Blasi R, Morin F, Vercellino L, Chevalier MF, Desnoyer A, de Jorna R, Madelaine I, Parquet N, Brignier AC, Thieblemont C, Larghero J, Caillat-Zucman S, Mebarki M. Cuffel A, et al. Among authors: thieblemont c. Blood Adv. 2022 Aug 9;6(15):4657-4660. doi: 10.1182/bloodadvances.2022007057. Blood Adv. 2022. PMID: 35728051 Free PMC article. No abstract available.
[Eligibility of patients for CAR T-cell: Expert opinion-based collaborative work by the SFGM-TC].
Beauvais D, Bachy E, Baruchel A, Bay JO, Caillot D, Cartron G, Damaj G, Furst S, Le Gouill S, Morschhauser F, Rabian F, Rubio MT, Thieblemont C, Yakoub-Agha I. Beauvais D, et al. Among authors: thieblemont c. Bull Cancer. 2021 Jul-Aug;108(7-8):725-729. doi: 10.1016/j.bulcan.2020.10.017. Epub 2021 Jan 7. Bull Cancer. 2021. PMID: 33423776 Review. French.
A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma.
Bachy E, Le Gouill S, Di Blasi R, Sesques P, Manson G, Cartron G, Beauvais D, Roulin L, Gros FX, Rubio MT, Bories P, Bay JO, Llorente CC, Choquet S, Casasnovas RO, Mohty M, Guidez S, Joris M, Loschi M, Carras S, Abraham J, Chauchet A, Drieu La Rochelle L, Deau-Fischer B, Hermine O, Gastinne T, Tudesq JJ, Gat E, Broussais F, Thieblemont C, Houot R, Morschhauser F. Bachy E, et al. Among authors: thieblemont c. Nat Med. 2022 Oct;28(10):2145-2154. doi: 10.1038/s41591-022-01969-y. Epub 2022 Sep 22. Nat Med. 2022. PMID: 36138152 Free PMC article.
Aflibercept-mediated early angiogenic changes in aggressive B-cell lymphoma.
Romero M, Brière J, de Bazelaire C, Lebœuf C, Wang L, Ratajczak P, Sibon D, de Kerviler E, Thieblemont C, Janin A. Romero M, et al. Among authors: thieblemont c. Cancer Chemother Pharmacol. 2011 Nov;68(5):1135-43. doi: 10.1007/s00280-011-1589-9. Epub 2011 Mar 5. Cancer Chemother Pharmacol. 2011. PMID: 21380563
Central nervous system relapse in patients over 80 years with diffuse large B-cell lymphoma: an analysis of two LYSA studies.
Cabannes-Hamy A, Peyrade F, Jardin F, Emile JF, Delwail V, Mounier N, Haioun C, Perrot A, Fitoussi O, Lara D, Delarue R, André M, Offner F, Ghesquières H, Pascal L, Soussain C, Lazarovici J, Schiano JM, Gaulard P, Tilly H, Thieblemont C; LYSA; lymphoma study association. Cabannes-Hamy A, et al. Among authors: thieblemont c. Cancer Med. 2018 Mar;7(3):539-548. doi: 10.1002/cam4.1139. Epub 2018 Feb 23. Cancer Med. 2018. PMID: 29473343 Free PMC article. Clinical Trial.
405 results